VivoSeq
Oncology

Biochemically Recurrent Prostate Carcinoma

2

Pipeline Programs↗

2

Active Trials↗

0

Companies Involved↗

Biochemically Recurrent Prostate Carcinoma is an early-stage landscape with 2 programs across 0 companies. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Flotufolastat F-18 Gallium

Blue Earth Diagnostics

Phase 2
No programs
Phase 31

Antiandrogen Therapy

University of Washington

Approved
No programs

Analysis

Modality Breakdown

2programs
Small molecule150%
Radiopharmaceutical150%

Modality classified for 100% of 2 pipeline programs.

Analysis

Trial Status

2

clinical trials

Recruiting2 · 100%

Clinical Trials

Trial Activity

Randomized Phase III Trial of SBRT Versus Hypofractionated Radiotherapy for Salvage of Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma After Radical Prostatectomy
Recruiting·MMayo Clinic·Phase 3·NCT06205316·118 enrolled
ENLIGHTEN: Detection by POSLUMA Following Negative Other PET-PSMA Imaging
Recruiting·NNorthwestern University·Phase 1·NCT06813898·27 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)